TIAN related Inflammatory Marker Screening Service

TIAN and Inflammatory Marker Screening Service for CAR-T Toxicity Management Solutions

Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are well-recognized complications of CAR-T therapy, a distinct entity termed tumor inflammation-associated neurotoxicity (TIAN) has emerged as a critical consideration, particularly in the context of CNS tumors. TIAN is characterized by localized neurotoxicity arising from inflammation within the CNS tumor microenvironment. This localized inflammation can manifest in two primary forms: Type 1 TIAN, driven by peritumoral edema leading to increased intracranial pressure and potentially life-threatening herniation; and Type 2 TIAN, resulting from neural-immune interactions that disrupt local neural function, even in the absence of significant edema. This distinction from the more systemic toxicities of CRS and ICANS is paramount for accurate diagnosis, appropriate management, and improved patient outcomes. The unique pathophysiology of TIAN, often occurring in the complex setting of pre-existing CNS pathology, necessitates specialized diagnostic and monitoring approaches.

Fig.1 A schematic of CRS and ICANS in CART therapy.¹

TIAN related Inflammatory Markers

Specific inflammatory markers implicated in CAR-T-related neurotoxicity, and potentially relevant to TIAN, include:

• Interleukin-6 (IL-6): Elevated levels are associated with increased risk and severity of ICANS and may also serve as an indicator of TIAN related inflammation.
• C-reactive protein (CRP): An acute-phase reactant that may be elevated in patients with TIAN, reflecting the inflammatory burden within the CNS.
• Ferritin: Elevated levels can indicate systemic inflammation and have been linked to ICANS, suggesting a potential role in TIAN pathogenesis.
• Other Cytokines: Pro-inflammatory cytokines such as IL-1, TNF-α, and IFN-γ, as well as chemokines like MCP-1, may contribute to the neuroinflammatory cascade in TIAN.
• Endothelial Activation Markers: Markers of endothelial activation, such as angiopoietin-2 (ANG-2) and von Willebrand factor, reflect vascular disruption and blood-brain barrier (BBB) permeability, which are critical components of TIAN pathophysiology.

Our TIAN related Cytokine Analysis Services

Creative Biolabs offers a comprehensive suite of services designed to support the development and implementation of inflammatory marker screening strategies for TIAN management. Our expertise in cytokine and biomarker analysis, coupled with our state-of-the-art laboratory facilities, positions us as a valuable partner for researchers, clinicians, and pharmaceutical companies working in the field of CAR-T cell therapy.

Creative Biolabs' services encompass a wide range of analytical techniques, including:

Our Advantages

Creative Biolabs offers several key advantages that make us an ideal partner for TIAN related research and clinical applications:

• State-of-the-Art Technology
• Customized Solutions
• Commitment to Quality
• Collaborative Approach

FAQs

Contact Us

To learn more about Creative Biolabs' TIAN related inflammatory marker screening services and how we can support your research or clinical needs, please contact us today.

Reference

1. Levstek, Lucija et al. "Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives." Frontiers in immunology vol. 15 1378944. 15 Mar. 2024, doi:10.3389/fimmu.2024.1378944. Distributed under Open Access License CC BY 4.0, without modification.